|Bid||6.0800 x 900|
|Ask||6.0900 x 800|
|Day's Range||5.9200 - 6.1100|
|52 Week Range||2.6600 - 7.2400|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.90|
OPKO Health's (OPK) partner VFMCRP gets regulatory nod from Health Canada to market flagship RAYALDEE; benefits patients diagnosed with chronic kidney disease.
On Monday, July 16, 2018, the NASDAQ Composite and the S&P 500 edged 0.26% and 0.10% lower, respectively at the closing bell, while the Dow Jones Industrial Average stayed bullish, finishing marginally higher by 0.18%. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Onconova Therapeutics Inc. (NASDAQ: ONTX), Ophthotech Corp. (NASDAQ: OPHT), OPKO Health Inc. (NASDAQ: OPK), and OvaScience Inc. (NASDAQ: OVAS).
MIAMI, July 16, 2018-- OPKO Health, Inc. announced today that the Company’ s partner Vifor Fresenius Medical Care Renal Pharma has received approval from Health Canada to market RAYALDEE ® in Canada for ...
Opko Health’s (OPK) Rayaldee generated revenues of $3.7 million in the first quarter. Rayaldee had a solid uptake in the first quarter, and it continued in the second quarter. According to IMS Health data, total Rayaldee prescriptions had 730% year-over-year growth in the first quarter and 38% growth sequentially.
Opko Health generated revenues of $254.9 million in the first quarter compared to $266.4 million in the first quarter of 2017, reflecting a 13.9% YoY (year-over-year) decline.
On July 11, Opko Health (OPK) stock closed at $6.01, which represents 126% growth from its 52-week low of $2.66 in March. On Tuesday, July 3, Opko Health stock closed at $4.76 and reached $6.01 on Thursday, July 11, which represents 24% growth over the last week. Opko Health stock saw consistent growth over the last week with 7.87% and 5.95% growth on July 6 and July 9, respectively.
NEW YORK, NY / ACCESSWIRE / July 10, 2018 / U.S. equities continued to push higher on Monday, as strong economic data counters worries on rising trade tensions. The Dow Jones Industrial Average advanced ...
NEW YORK, NY / ACCESSWIRE / July 9, 2018 / U.S. equities posted solid gains on Friday, ending the week on a positive note, supported by a stronger-than-expected jobs report. The Dow Jones Industrial Average ...
In this article I am going to calculate the intrinsic value of OPKO Health Inc (NASDAQ:OPK) by taking the foreast future cash flows of the company and discounting them backRead More...
Exome sequencing is a process by which the protein-coding genes in the human genome are sequenced. It is used to help diagnose disease by identifying variations in these genes that may lead to a variety of neurological, metabolic or other disorders. Over the past three years, GeneDx has helped discover and publish more than 62 disease-causing genes, thereby contributing to the phenotypic, or observable characteristics, involved in identifying and further understanding developmental delay and intellectual disability. GeneDx has grown in exome volume by a compound annual growth rate of 55% since its inception. With over 100 professionals dedicated to exomes and genomes, including MDs, PhDs and genetic counselors, GeneDx has developed a suite of patient-focused exome and genome tests for a variety of clinical indications and scenarios, including family-based testing, rapid testing for critically ill patients, prenatal testing and exome testing in parallel with mitochondrial genetic testing.
NEW YORK, NY / ACCESSWIRE / June 11, 2018 / U.S. markets finished higher and logged strongest week in months as investors shrug off tensions between U.S. and its allies. The Dow Jones Industrial Average ...
Based on preclinical and Phase 2 data, the use of the dual agonist, OPK88003, once-weekly with an optimized dosing regimen, could more effectively improve glucose control, increase weight loss and improve the lipid profile in type 2 diabetics compared with the currently available GLP-1 medicines.
Opko's shares benefited from a better-than-expected first-quarter earnings release last month, but the company's good fortunes didn't last long.
NEW YORK , June 5, 2018 /PRNewswire/ -- Cadus Corporation (KDUS) Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with the proposed sale of Cadus to Starfire ...
Jim Cramer said on CNBC's "Mad Money Lightning Round" he can no longer recommend Altria Group Inc (NYSE: MO ) as a buy. He's concerned about competition from the Juul device. Cramer doesn't ...
NEW YORK, NY / ACCESSWIRE / May 22, 2018 / Pomerantz LLP is investigating claims on behalf of investors of OPKO Health, Inc. ("OPKO" or the "Company") (OPK). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. 9980. The investigation concerns whether OPKO and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
A crossover of the two lines indicates a trend change. Genworth Financial, Inc. (NYSE: GNW) had a predictive moving average crossover to the upside in late-April indicating a bullish trend. Under Armour, Inc. (NYSE: UAA) also had a bullish crossover in late-April, indicating that an uptrend was beginning.
Stock Research Monitor: NBIX, NVAX, and ONTX LONDON, UK / ACCESSWIRE / May 22, 2018 / If you want a free Stock Review on OPK sign up now at www.wallstequities.com/registration . On Monday, benchmark US ...
NEW YORK , May 21, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of OPKO Health, Inc. ("OPKO" or the "Company") (NASDAQ: OPK). Such investors ...
The biotech analysts at Cantor Fitzgerald have a packed calendar: here are some of the dates they’re tracking and why they’re important. Mallinckrodt PLC (NYSE: MNK ) is expected to release Phase 4 interim ...